BURLINGAME, Calif., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage
biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced that
it will present preclinical data, and preliminary biomarker data from its ongoing Phase 1/1b study of CPI-444 as a single agent,
and in combination with Genentech’s TECENTRIQ™ (atezolizumab), in both oral and poster presentations at the Second
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, which is taking place from
September 25-28 in New York.
Following are details of the oral and poster presentations.
Abstract Title: CPI-444: A potent and selective inhibitor of A2AR induces antitumor responses alone and in
combination with anti-PD-L1 in preclinical and clinical studies
Presenter: Stephen Willingham, Ph.D., senior scientist, Corvus
Oral Session: Plenary Session 2: New Checkpoints
Oral Session Date, Time and Location: Sunday, September 25, 1:30-4:40 p.m. ET, Sheraton Metropolitan Ballroom,
Sheraton New York Times Square Hotel
Poster Session: Poster Session A: New Checkpoints
Poster Number: A048
Poster Presentation Date, Time and Location: Sunday, September 25, 5:00-7:30 p.m. ET, Americas Hall I, New York
Hilton Midtown
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of small
molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial
immune checkpoints and reprogram immune T-cells. Corvus’ lead product, CPI-444, is a checkpoint inhibitor that is designed to
disable a tumor’s ability to subvert attack by the immune system by inhibiting adenosine in the tumor microenvironment. CPI-444 is
a small molecule that is taken orally. CPI-444 is currently being evaluated in a multicenter Phase 1/1b clinical trial in patients
with various solid tumors. This successive expansion cohort trial is examining the activity of CPI-444 both as a single agent and
in combination with TECENTRIQ™, Genentech's cancer immunotherapy. TECENTRIQ™ is a fully humanized monoclonal antibody targeting
protein programmed cell death ligand 1 (PD-L1). Corvus is conducting the trial with Genentech, a member of the Roche Group,
under a clinical trial collaboration the two companies entered into in October 2015. For more information, visit: www.corvuspharma.com.
Investor Contact: Jason Coloma, Ph.D. SVP and Chief Business Officer 650-900-4511 JColoma@corvuspharma.com Media Contact: Julie Normart, W2O Group 415-946-1087 jnormart@w2ogroup.com
